Research programme: haemophilia therapeutics - Amunix/Bioverativ

Drug Profile

Research programme: haemophilia therapeutics - Amunix/Bioverativ

Alternative Names: BIVV 001; BIVV 002; Blood coagulation factors recombinant - Amunix/Bioverativ; Factor IX recombinant - Amunix/Bioverativ; Factor VIIa recombinant - Amunix/Bioverativ; Factor VIII recombinant - Amunix/Bioverativ; FIXFc-XTEN; rFIXFc-XTEN; rFVIIIFc-VWF-XTEN; rFVIIIFc-XTEN-vWF; XTENylated Factor VIII

Latest Information Update: 10 Mar 2017

Price : $50

At a glance

  • Originator Amunix; Biogen Idec
  • Developer Amunix; Bioverativ
  • Class Blood coagulation factors; Recombinant fusion proteins
  • Mechanism of Action Blood coagulation factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haemophilia A; Haemophilia B

Most Recent Events

  • 22 Feb 2017 Swedish Orphan Biovitrum exercises its option to add candidate, rFIXFc XTEN to the company’s collaboration agreement with Bioverativ
  • 01 Feb 2017 Biogen has separated its Haemophilia Business under a new company Bioverativ
  • 01 Feb 2017 Bioverativ plans a clinical trial for BIVV 001 for Haemophilia A
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top